Skip to main content

Pasithea Therapeutics Corp. (KTTA)

NASDAQ: KTTA · Delayed Price · USD
-0.01 (-0.37%)
After-hours:Oct 26, 2021 7:30 PM EDT
0.04 (1.50%)
At close: Oct 26, 4:00 PM

Company Description

Pasithea Therapeutics is a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders.

As of March 26, 2021, the Company had not commenced core operations. Epidemiological data indicate neuropsychiatric disorders as being some of the most prevalent, devastating, and yet poorly treated illnesses.

Our biotech operations will focus on developing drugs that target the pathophysiology underlying such disorders rather than symptomatic treatments, with the goal of developing new pharmacological agents that display significant advantages over conventional therapies with respect to efficacy and tolerability.

We aim to focus on mechanism-based immune treatments for the treatment of these disorders. Our secondary operations are focused on establishing anti-depression clinics across the United Kingdom and providing business support services to similar entities in the United States and using psychiatric assessment combined with physician/medical providers to administer intravenous infusions of ketamine.

As of the date of this prospectus, ketamine is gaining grounds as a promising treatment for some cases of major depression.

Pasithea Therapeutics Corp.
CountryUnited States
IPO DateSep 15, 2021
CEODr. Tiago Reis Marques

Contact Details

1111 Lincoln Road, Suite 500
Miami Beach, FL 33139
United States

Stock Details

Ticker SymbolKTTA
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
IPO Price$5.00
CIK Code1841330
ISIN NumberUS70261F1030
Employer ID85-1591963

Key Executives

Dr. Tiago Reis MarquesChief Executive Officer and Director
Prof. Lawrence Steinman BA, M.D.Executive Chairman and Co-Founder
Stanley M. GlossChief Financial Officer
Dr. Yassine BendiabdallahChief Operating Officer, Head of UK Clinics and Director